Prelym

HSCT recipients are at increased risk of developing severe and fatal viral infections caused by:

  • Adenovirus (AdV)
  • BK virus (BKV)
  • Cytomegalovirus (CMV)
  • Epstein-Barr virus (EBV)
  • Human Herpesvirus-6 (HHV-6)
 Currently there are limited therapeutic options with broad antiviral specificity providing protection against viral infection.

Prelym

Prelym is a personalized T cell product, made from the patient’s specific HSCT donor, designed to prevent the emergence of viral infections in high-risk patients. Depending on the individual HSCT donor, Prelym has been shown to prevent up to 5 viruses (AdV, BKV, CMV, EBV, HHV-6). Prelym is currently being evaluated in a Phase 1/2 clinical study which is open for patient recruitment at Texas Children’s Hospital and the Methodist Hospital in Houston, TX. For more information, please visit ClincialTrials.gov: NCT01570283

ClincialTrials.gov: NCT01570283